1. Medtech Insight
  2. >>Business

Trump's Triumph: Markets React, But 'Wait-And-See' Approach Advised For Medtech

 
• By Tina Tan

Donald Trump's victory over Hillary Clinton in the US presidential election have sent many reeling in shock, but what impact has this had on health-care stocks the morning after, and what longer-term repercussions would a Trump administration have on the medtech industry?

Donald Trump

When life deals a blow, it's usually the big and strong that can withstand the impact better than the small and weak. This seems to be the case for health-care stocks and the reaction of the markets on Nov. 9, the day after the US voted for its next president and Donald Trump emerged as the surprise victor.

"The initial reaction [to the US election result] is one of a 'risk-off' attitude," said Nick Keher, director, health-care equity...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Brazil Asks Stakeholders To Weigh In On Ways To Improve Country’s Trial Environment

 
• By Francesca Bruce

Brazil is planning to update its National Clinical Research Action Plan to make the country a more competitive location to conduct R&D.

PathAI Expands AISight Dx Label With PCCP-Guided Addition Of Roche Scanners

 
• By Natasha Barrow

Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.

Ketryx Raises $39M To Accelerate Regulated AI Development Platform

 
• By Shubham Singh

Ketryx relies on a combination of continuous validation, testing, and human oversight to ensure the platform remains compliant and reliable as AI capabilities evolve, CEO Kaminski said.

Monogram Sets Sept. 30 Shareholder Vote on $177M Zimmer Biomet Deal, $11M Fee If Terminated

 
• By Shubham Singh

Under the deal, Monogram shareholders will receive $4.04 per share in cash, plus a contingent value right (CVR) that could deliver up to $12.37 per share in additional payments if milestone targets are achieved by 2030.

More from Medtech Insight

Execs On The Move: August 25–29, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

PathAI Expands AISight Dx Label With PCCP-Guided Addition Of Roche Scanners

 
• By Natasha Barrow

Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.

Ketryx Raises $39M To Accelerate Regulated AI Development Platform

 
• By Shubham Singh

Ketryx relies on a combination of continuous validation, testing, and human oversight to ensure the platform remains compliant and reliable as AI capabilities evolve, CEO Kaminski said.